Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10838819 | Pharmacology Biochemistry and Behavior | 2005 | 8 Pages |
Abstract
Intracerebroventricular (i.c.v.) injections of bombesin (BN) and gastrin-releasing peptide (GRP) dose-dependently decreased food intake in male Wistar rats fasted for 17 h. Neuromedin B (NMB) did not show any effect on food intake. After BN administration, locomotor activity did not significantly change, compared with a vehicle-injected group. The anorexia induced by BN (0.3 μg) was perfectly inhibited by pretreatment with a GRP-receptor antagonist, [d-Tyr6]BN(6-13) methyl ester (10 μg), an NO synthase inhibitor, l-nitro-arginine (30 μg), and a PKG inhibitor, H-9 (2 μg). The cGMP concentration in the hypothalamus increased 1 h after administration when compared with the vehicle-injected group. On the other hand, an NMB-receptor antagonist, BIM23127 (10 μg), and the protein kinase (PK) C inhibitors, chelerythrine (2 μg) and Gö6983 (2 μg), inhibited only the late phase of the anorexia. A PKC activator, phorbol 12, 13-dibutyrate (3 μg), injected into the ventricle decreased food intake. These findings suggest that BN suppresses food intake mainly mediated through the GRP receptor and NO-cGMP-PKG pathway, and NMB receptor and PKC is partly involved in the late phase of the anorexia.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Hiromi Tsushima, Mayumi Mori,